{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T10:32:49Z","timestamp":1782124369561,"version":"3.54.5"},"publisher-location":"Berlin, Heidelberg","reference-count":132,"publisher":"Springer Berlin Heidelberg","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1007\/82_2019_175","type":"book-chapter","created":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T19:03:47Z","timestamp":1563908627000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Chikungunya Virus Vaccines: Platforms, Progress, and Challenges"],"prefix":"10.1007","author":[{"given":"Victor R.","family":"DeFilippis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,24]]},"reference":[{"key":"175_CR1","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/nm.2105","volume":"16","author":"W Akahata","year":"2010","unstructured":"Akahata W, Yang Z-Y, Andersen H, Sun S, Holdaway HA, Kong W-P, Lewis MG, Higgs S, Rossmann MG, Rao S, Nabel GJ (2010) A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nature Medicine 16:334\u2013338","journal-title":"Nature Medicine"},{"key":"175_CR2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1742-4933-4-9","volume":"4","author":"R Aspinall","year":"2007","unstructured":"Aspinall R, Del Giudice G, Effros RB, Grubeck-Loebenstein B, Sambhara S (2007) Challenges for vaccination in the elderly. Immun Ageing 4:9","journal-title":"Immun Ageing"},{"key":"175_CR3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41426-017-0010-0","volume":"7","author":"H Auerswald","year":"2018","unstructured":"Auerswald H, Boussioux C, In S, Mao S, Ong S, Huy R, Leang R, Chan M, Duong V, Ly S, Tarantola A, Dussart P (2018) Broad and long-lasting immune protection against various Chikungunya genotypes demonstrated by participants in a cross-sectional study in a Cambodian rural community. Emerg Microbes Infect 7:13","journal-title":"Emerg Microbes Infect"},{"key":"175_CR4","unstructured":"Bloch D (2017) The Cost and burden of Chikungunya in the Americas 1\u201334"},{"key":"175_CR5","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.tips.2017.06.002","volume":"38","author":"SR Bonam","year":"2017","unstructured":"Bonam SR, Partidos CD, Halmuthur SKM, Muller S (2017) An overview of novel adjuvants designed for improving vaccine efficacy. Trends Pharmacol Sci 38:771\u2013793","journal-title":"Trends Pharmacol Sci"},{"key":"175_CR6","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.3389\/fimmu.2017.01772","volume":"8","author":"F Borriello","year":"2017","unstructured":"Borriello F, Pietrasanta C, Lai JCY, Walsh LM, Sharma P, O\u2019Driscoll DN, Ramirez J, Brightman S, Pugni L, Mosca F, Burkhart DJ, Dowling DJ, Levy O (2017) Identification and characterization of stimulator of interferon genes as a robust adjuvant target for early life immunization. Front Immunol 8:1772","journal-title":"Front Immunol"},{"key":"175_CR7","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1016\/j.vaccine.2013.05.086","volume":"31","author":"S Brandler","year":"2013","unstructured":"Brandler S, Ruffi\u00e9 C, Combredet C, Brault J-B, Najburg V, Prevost M-C, Habel A, Tauber E, Despr\u00e8s P, Tangy F (2013) A recombinant measles vaccine expressing Chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with Chikungunya virus. Vaccine 31:3718\u20133725","journal-title":"Vaccine"},{"key":"175_CR8","doi-asserted-by":"crossref","first-page":"e0005637","DOI":"10.1371\/journal.pntd.0005637","volume":"11","author":"R Broeckel","year":"2017","unstructured":"Broeckel R, Fox JM, Haese N, Kreklywich CN, Sukulpovi-Petty S, Legasse A, Smith PP, Denton M, Corvey C, Krishnan S, Colgin LMA, Ducore RM, Lewis AD, Axthelm MK, Mandron M, Cortez P, Rothblatt J, Rao E, Focken I, Carter K, Sapparapau G, Crowe JE, Diamond MS, Streblow DN (2017) Therapeutic administration of a recombinant human monoclonal antibody reduces the severity of Chikungunya virus disease in rhesus macaques. PLoS Negl Trop Dis 11:e0005637","journal-title":"PLoS Negl Trop Dis"},{"key":"175_CR102","doi-asserted-by":"crossref","unstructured":"Cardiel MH, Pons-Estel BA, Sacnun MP, Wojdyla D, Saurit V, Marcos JC, Pinto MRC, Cordeiro de Azevedo AB, da Silveira IG, Radominski SC, Ximenes AC, Massardo L, Ballesteros F, Rojas-Villarraga A, O\u00f1ate RV, Hernandez MP, Esquivel-Valerio JA, Garc\u00eda-De La Torre I, Khoury VJ, Mill\u00e1n A, Soriano ER, GLADAR (2012) Treatment of early rheumatoid arthritis in a multinational inception cohort of Latin American patients: the GLADAR experience. J Clin Rheumatol 18:327\u2013335","DOI":"10.1097\/RHU.0b013e31826d6610"},{"key":"175_CR9","doi-asserted-by":"crossref","unstructured":"Chang L-J, Dowd KA, Mendoza FH, Sounders JG, Sitar S, Plummer SH, Yamshchikov G, Sarwar UN, Hu Z, Enama ME, Bailer RT, Koup RA, Schwartz RM, Akahata W, Nabel GJ, Mascola JR, Pierson TC, Graham BS, Ledgerwood JE, Team TV3S (2014) Safety and tolerability of Chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. The Lancet 384:2046\u20132052","DOI":"10.1016\/S0140-6736(14)61185-5"},{"key":"175_CR10","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S2352-4642(17)30021-4","volume":"1","author":"C Charlier","year":"2017","unstructured":"Charlier C, Beaudoin M-C, Couderc T, Lortholary O, Lecuit M (2017) Arboviruses and pregnancy: maternal, fetal, and neonatal effects. Lancet Child Adolesc Health 1:134\u2013146","journal-title":"Lancet Child Adolesc Health"},{"key":"175_CR11","doi-asserted-by":"crossref","unstructured":"Chattopadhyay A, Wang E, Seymour R, Weaver SC, Rose JK (2012) A chimeric vesiculo\/alphavirus is an effective Alphavirus Vaccine. J Virol","DOI":"10.1128\/JVI.01860-12"},{"key":"175_CR12","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.4269\/ajtmh.2010.10-0290","volume":"83","author":"C-I Chen","year":"2010","unstructured":"Chen C-I, Clark DC, Pesavento P, Lerche NW, Luciw PA, Reisen WK, Brault AC (2010) Comparative pathogenesis of epidemic and enzootic Chikungunya viruses in a pregnant Rhesus macaque model. Am J Trop Med Hyg 83:1249\u20131258","journal-title":"Am J Trop Med Hyg"},{"key":"175_CR13","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1016\/j.vaccine.2013.05.059","volume":"31","author":"H Chu","year":"2013","unstructured":"Chu H, Das SC, Fuchs JF, Suresh M, Weaver SC, Stinchcomb DT, Partidos CD, Osorio JE (2013) Deciphering the protective role of adaptive immunity to CHIKV\/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model. Vaccine 31:3353\u20133360","journal-title":"Vaccine"},{"key":"175_CR14","doi-asserted-by":"crossref","first-page":"e0004960","DOI":"10.1371\/journal.pntd.0004960","volume":"10","author":"C-L Chua","year":"2016","unstructured":"Chua C-L, Sam I-C, Merits A, Chan Y-F (2016) Antigenic variation of East\/Central\/South African and Asian Chikungunya virus genotypes in neutralization by immune Sera. PLoS Negl Trop Dis 10:e0004960","journal-title":"PLoS Negl Trop Dis"},{"key":"175_CR15","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","volume":"33","author":"RL Coffman","year":"2010","unstructured":"Coffman RL, Sher A, Seder RA (2010) Vaccine adjuvants: putting innate immunity to work. Immunity 33:492\u2013503","journal-title":"Immunity"},{"key":"175_CR16","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1016\/j.vaccine.2017.05.097","volume":"35","author":"B-AG Coller","year":"2017","unstructured":"Coller B-AG, Blue J, Das R, Dubey S, Finelli L, Gupta S, Helmond F, Grant-Klein RJ, Liu K, Simon J, Troth S, VanRheenen S, Waterbury J, Wivel A, Wolf J, Heppner DG, Kemp T, Nichols R, Monath TP (2017) Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic. Vaccine 35:4465\u20134469","journal-title":"Vaccine"},{"key":"175_CR17","doi-asserted-by":"crossref","first-page":"11546","DOI":"10.1128\/JVI.77.21.11546-11554.2003","volume":"77","author":"C Combredet","year":"2003","unstructured":"Combredet C, Labrousse V, Mollet L, Lorin C, Delebecque F, Hurtrel B, McClure H, Feinberg MB, Brahic M, Tangy F (2003) A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice. J Virol 77:11546\u201311554","journal-title":"J Virol"},{"key":"175_CR18","doi-asserted-by":"crossref","unstructured":"Couderc T, Chretien F, Schilte C, Disson O, Brigitte M (2008a) A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease. PLoS \u2026","DOI":"10.1371\/journal.ppat.0040029"},{"key":"175_CR19","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1371\/journal.ppat.0040029","volume":"4","author":"T Couderc","year":"2008","unstructured":"Couderc T, Chr\u00e9tien F, Schilte C, Disson O, Brigitte M, Guivel-Benhassine F, Touret Y, Barau G, Cayet N, Schuffenecker I, Despr\u00e8s P, Arenzana-Seisdedos F, Michault A, Albert ML, Lecuit M (2008b) A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease. PLoS Pathog 4:e29","journal-title":"PLoS Pathog"},{"key":"175_CR20","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1086\/600381","volume":"200","author":"T Couderc","year":"2009","unstructured":"Couderc T, Khandoudi N, Grandadam M, Visse C, Gangneux N, Bagot S, Prost J-F, Lecuit M (2009) Prophylaxis and therapy for Chikungunya virus infection. J Infect Dis 200:516\u2013523","journal-title":"J Infect Dis"},{"key":"175_CR21","first-page":"55","volume":"330","author":"RL de Swart","year":"2009","unstructured":"de Swart RL, DeSwart RL (2009) Measles studies in the macaque model. Curr Top Microbiol Immunol 330:55\u201372","journal-title":"Curr Top Microbiol Immunol"},{"key":"175_CR22","doi-asserted-by":"crossref","unstructured":"de Brito CAA, Sohsten AKAV, Leit\u00e3o CC de S, Brito R de CCM de, Valadares LDDA, Fonte CAMD, Mesquita ZB de, Cunha RV, Luz K, Le\u00e3o HMC, Brito CM de, Frutuoso LCV (2016) Pharmacologic management of pain in patients with Chikungunya: a guideline. Rev Soc Bras Med Trop 49:668\u2013679","DOI":"10.1590\/0037-8682-0279-2016"},{"key":"175_CR23","doi-asserted-by":"crossref","first-page":"e1649","DOI":"10.1371\/journal.pntd.0001649","volume":"6","author":"D Diallo","year":"2012","unstructured":"Diallo D, Sall AA, Buenemann M, Chen R, Faye O, Diagne CT, Faye O, Ba Y, Dia I, Watts D, Weaver SC, Hanley KA, Diallo M (2012) Landscape ecology of sylvatic chikungunya virus and mosquito vectors in southeastern Senegal. PLoS Negl Trop Dis 6:e1649","journal-title":"PLoS Negl Trop Dis"},{"key":"175_CR24","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1016\/j.vaccine.2013.05.091","volume":"31","author":"SJ Draper","year":"2013","unstructured":"Draper SJ, Cottingham MG, Gilbert SC (2013) Utilizing poxviral vectored vaccines for antibody induction-progress and prospects. Vaccine 31:4223\u20134230","journal-title":"Vaccine"},{"key":"175_CR25","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1128\/am.19.2.321-325.1970","volume":"19","author":"KH Eckels","year":"1970","unstructured":"Eckels KH, Harrison VR, Hetrick FM (1970) Chikungunya virus vaccine prepared by Tween-ether extraction. Appl Microbiol 19:321\u2013325","journal-title":"Appl Microbiol"},{"key":"175_CR26","doi-asserted-by":"crossref","first-page":"681","DOI":"10.4269\/ajtmh.2000.62.681","volume":"62","author":"R Edelman","year":"2000","unstructured":"Edelman R, Tacket CO, Wasserman SS, Bodison SA, Perry JG, Mangiafico JA (2000) Phase II safety and immunogenicity study of live Chikungunya virus vaccine TSI-GSD-218. Am J Trop Med Hyg 62:681\u2013685","journal-title":"Am J Trop Med Hyg"},{"key":"175_CR27","doi-asserted-by":"crossref","unstructured":"Enserink M (2007) Infectious diseases. Chikungunya: no longer a third world disease. Science. American Association for the Advancement of Science","DOI":"10.1126\/science.318.5858.1860"},{"key":"175_CR28","doi-asserted-by":"crossref","first-page":"e0004119","DOI":"10.1371\/journal.pntd.0004119","volume":"9","author":"JH Erasmus","year":"2015","unstructured":"Erasmus JH, Needham J, Raychaudhuri S, Diamond MS, Beasley DWC, Morkowski S, Salje H, Fernandez-Salas I, Kim DY, Frolov I, Nasar F, Weaver SC (2015) Utilization of an eilat virus-based chimera for serological detection of Chikungunya infection. PLoS Negl Trop Dis 9:e0004119","journal-title":"PLoS Negl Trop Dis"},{"key":"175_CR29","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nm.4253","volume":"23","author":"JH Erasmus","year":"2016","unstructured":"Erasmus JH, Auguste AJ, Kaelber JT, Luo H, Rossi SL, Fenton K, Leal G, Kim DY, Chiu W, Wang T, Frolov I, Nasar F, Weaver SC (2016) A Chikungunya fever vaccine utilizing an insect-specific virus platform. Nat Med 23:192\u2013199","journal-title":"Nat Med"},{"key":"175_CR30","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1080\/21645515.2017.1383575","volume":"13","author":"K Ewer","year":"2017","unstructured":"Ewer K, Sebastian S, Spencer AJ, Gilbert S, Hill AVS, Lambe T (2017) Chimpanzee adenoviral vectors as vaccines for outbreak pathogens. Hum Vaccin Immunother 13:3020\u20133032","journal-title":"Hum Vaccin Immunother"},{"key":"175_CR31","doi-asserted-by":"crossref","unstructured":"Fox JM, Long F, Edeling MA, Lin H, van Duijl-Richter MKS, Fong RH, Kahle KM, Smit JM, Jin J, Simmons G, Doranz BJ, Crowe JE Jr, Fremont DH, Rossmann MG, Diamond MS (2015) Broadly neutralizing alphavirus antibodies bind an epitope on E2 and inhibit entry and egress. Cell 1\u201314","DOI":"10.1016\/j.cell.2015.10.050"},{"key":"175_CR32","doi-asserted-by":"crossref","first-page":"e0004281","DOI":"10.1371\/journal.pntd.0004281","volume":"10","author":"B Galatas","year":"2016","unstructured":"Galatas B, Ly S, Duong V, Baisley K, Nguon K, Chan S, Huy R, Ly S, Sorn S, Som L, Buchy P, Tarantola A (2016) Long-lasting immune protection and other epidemiological findings after Chikungunya emergence in a Cambodian rural community, April 2012. PLoS Negl Trop Dis 10:e0004281","journal-title":"PLoS Negl Trop Dis"},{"key":"175_CR33","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1128\/JVI.03418-13","volume":"88","author":"J Garc\u00eda-Arriaza","year":"2014","unstructured":"Garc\u00eda-Arriaza J, Cepeda V, Halleng\u00e4rd D, Sorzano C\u00d3S, K\u00fcmmerer BM, Liljestr\u00f6m P, Esteban M (2014) A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against Chikungunya infection. J Virol 88:3527\u20133547","journal-title":"J Virol"},{"key":"175_CR34","doi-asserted-by":"crossref","first-page":"8021","DOI":"10.1128\/JVI.02603-09","volume":"84","author":"J Gardner","year":"2010","unstructured":"Gardner J, Anraku I, Le TT, Larcher T, Major L, Roques P, Schroder WA, Higgs S, Suhrbier A (2010) Chikungunya virus arthritis in adult wild-type mice. J Virol 84:8021\u20138032","journal-title":"J Virol"},{"key":"175_CR35","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.virol.2011.12.020","volume":"425","author":"CL Gardner","year":"2012","unstructured":"Gardner CL, Burke CW, Higgs ST, Klimstra WB, Ryman KD (2012) Interferon-alpha\/beta deficiency greatly exacerbates arthritogenic disease in mice infected with wild-type chikungunya virus but not with the cell culture-adapted live-attenuated 181\/25 vaccine candidate. Virology 425:103\u2013112","journal-title":"Virology"},{"key":"175_CR36","doi-asserted-by":"crossref","first-page":"e2719","DOI":"10.1371\/journal.pntd.0002719","volume":"8","author":"CL Gardner","year":"2014","unstructured":"Gardner CL, Hritz J, Sun C, Vanlandingham DL, Song TY, Ghedin E, Higgs S, Klimstra WB, Ryman KD (2014) Deliberate attenuation of chikungunya virus by adaptation to heparan sulfate-dependent infectivity: a model for rational arboviral vaccine design. PLoS Negl Trop Dis 8:e2719","journal-title":"PLoS Negl Trop Dis"},{"key":"175_CR37","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/biot.201400388","volume":"10","author":"Y Genzel","year":"2015","unstructured":"Genzel Y (2015) Designing cell lines for viral vaccine production: Where do we stand? Biotechnol J 10:728\u2013740","journal-title":"Biotechnol J"},{"key":"175_CR38","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1111\/jgs.15004","volume":"65","author":"L Godaert","year":"2017","unstructured":"Godaert L, Najioullah F, Bartholet S, Colas S, Yactayo S, Cabi\u00e9 A, Fanon J-L, C\u00e9saire R, Dram\u00e9 M (2017) Atypical clinical presentations of acute phase Chikungunya virus infection in older adults. J Am Geriatr Soc 65:2510\u20132515","journal-title":"J Am Geriatr Soc"},{"key":"175_CR39","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1093\/infdis\/jiw431","volume":"214","author":"L Goo","year":"2016","unstructured":"Goo L, Dowd KA, Lin T-Y, Mascola JR, Graham BS, Ledgerwood JE, Pierson TC (2016) A virus-like particle vaccine elicits broad neutralizing antibody responses in humans to All Chikungunya virus genotypes. J Infect Dis 214:1487\u20131491","journal-title":"J Infect Dis"},{"key":"175_CR40","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1128\/JVI.06449-11","volume":"86","author":"R Gorchakov","year":"2012","unstructured":"Gorchakov R, Wang E, Leal G, Forrester NL, Plante K, Rossi SL, Partidos CD, Adams AP, Seymour RL, Weger J, Borland EM, Sherman MB, Powers AM, Osorio JE, Weaver SC (2012) Attenuation of Chikungunya virus vaccine strain 181\/clone 25 is determined by two amino acid substitutions in the E2 envelope glycoprotein. J Virol 86:6084\u20136096","journal-title":"J Virol"},{"key":"175_CR41","doi-asserted-by":"crossref","first-page":"S482","DOI":"10.1093\/infdis\/jiw284","volume":"214","author":"NN Haese","year":"2016","unstructured":"Haese NN, Broeckel RM, Hawman DW, Heise MT, Morrison TE, Streblow DN (2016) Animal models of Chikungunya virus infection and disease. J Infect Dis 214:S482\u2013S487","journal-title":"J Infect Dis"},{"key":"175_CR42","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1128\/JVI.76.6.2730-2738.2002","volume":"76","author":"K Haglund","year":"2002","unstructured":"Haglund K, Leiner I, Kerksiek K, Buonocore L, Pamer E, Rose JK (2002) High-level primary CD8(+) T-cell response to human immunodeficiency virus type 1 gag and env generated by vaccination with recombinant vesicular stomatitis viruses. J Virol 76:2730\u20132738","journal-title":"J Virol"},{"key":"175_CR43","doi-asserted-by":"crossref","unstructured":"Hallengard D, Lum FM, Kummerer BM, Lulla A, Lulla V, Garcia-Arriaza J, Fazakerley JK, Roques P, Le Grand R, Merits A, Ng LFP, Esteban M, Liljestrom P (2014) Prime-boost immunization strategies against Chikungunya virus. J Virol","DOI":"10.1128\/JVI.01926-14"},{"key":"175_CR44","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1128\/JVI.03453-13","volume":"88","author":"D Halleng\u00e4rd","year":"2014","unstructured":"Halleng\u00e4rd D, Kakoulidou M, Lulla A, K\u00fcmmerer BM, Johansson DX, Mutso M, Lulla V, Fazakerley JK, Roques P, Le Grand R, Merits A, Liljestr\u00f6m P (2014) Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL\/6 mice. J Virol 88:2858\u20132866","journal-title":"J Virol"},{"key":"175_CR45","doi-asserted-by":"crossref","first-page":"643","DOI":"10.4049\/jimmunol.107.3.643","volume":"107","author":"VR Harrison","year":"1971","unstructured":"Harrison VR, Eckels KH, Bartelloni PJ, Hampton C (1971) Production and evaluation of a formalin-killed Chikungunya vaccine. J Immunol 107:643\u2013647","journal-title":"J Immunol"},{"key":"175_CR46","doi-asserted-by":"crossref","first-page":"13878","DOI":"10.1128\/JVI.02666-13","volume":"87","author":"DW Hawman","year":"2013","unstructured":"Hawman DW, Stoermer KA, Montgomery SA, Pal P, Oko L, Diamond MS, Morrison TE (2013) Chronic joint disease caused by persistent Chikungunya virus infection is controlled by the adaptive immune response. J Virol 87:13878\u201313888","journal-title":"J Virol"},{"key":"175_CR47","doi-asserted-by":"crossref","first-page":"e84695","DOI":"10.1371\/journal.pone.0084695","volume":"8","author":"JJ Hoarau","year":"2013","unstructured":"Hoarau JJ, Gay F, Pell\u00e9 O, Samri A, Jaffar-Bandjee MC, Gasque P, Autran B (2013) Identical strength of the T cell responses against E2, nsP1 and capsid CHIKV proteins in recovered and chronic patients after the epidemics of 2005\u20132006 in La Reunion Island. PLoS ONE 8:e84695","journal-title":"PLoS ONE"},{"key":"175_CR48","doi-asserted-by":"crossref","unstructured":"Hu M-M, Shu H-B (2018) Cytoplasmic mechanisms of recognition and defense of microbial nucleic acids. Annu Rev Cell Dev Biol","DOI":"10.1146\/annurev-cellbio-100617-062903"},{"key":"175_CR49","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/ni.3123","volume":"16","author":"A Iwasaki","year":"2015","unstructured":"Iwasaki A, Medzhitov R (2015) Control of adaptive immunity by the innate immune system. Nat Immunol 16:343\u2013353","journal-title":"Nat Immunol"},{"key":"175_CR50","doi-asserted-by":"crossref","unstructured":"Kam Y-W, Lee WWL, Simarmata D, Harjanto S, Teng T-S, Tolou H, Chow A, Lin RTP, Leo Y-S, REnia L, Ng LFP (2012) Longitudinal analysis of the human antibody response to Chikungunya virus infection: implications for serodiagnosis and vaccine development. J Virol 86:13005\u201313015","DOI":"10.1128\/JVI.01780-12"},{"key":"175_CR51","doi-asserted-by":"crossref","unstructured":"Kam Y-W, Simarmata D, Chow A, Her Z, Teng T-S, Ong EKS, REnia L, Leo Y-S, Ng LFP (2012a) Early appearance of neutralizing immunoglobulin G3 antibodies is associated with Chikungunya virus clearance and long-term clinical protection. J Infect Dis 205:1147\u20131154","DOI":"10.1093\/infdis\/jis033"},{"key":"175_CR52","doi-asserted-by":"crossref","unstructured":"Kam Y-W, Lum F-M, Teo T-H, Lee WWL, Simarmata D, Harjanto S, Chua C-L, Chan Y-F, Wee J-K, Chow A, Lin RTP, Leo Y-S, Le Grand R, Sam I-C, Tong J-C, Roques P, Wiesm\u00fcller K-H, REnia L, R\u00f6tzschke O, Ng LFP (2012b) Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein. EMBO Mol Med 4:330\u2013343","DOI":"10.1002\/emmm.201200213"},{"key":"175_CR53","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.virusres.2012.05.004","volume":"167","author":"M Khan","year":"2012","unstructured":"Khan M, Dhanwani R, Rao PVL, Parida M (2012) Subunit vaccine formulations based on recombinant envelope proteins of Chikungunya virus elicit balanced Th1\/Th2 response and virus-neutralizing antibodies in mice. Virus Research 167:236\u2013246","journal-title":"Virus Research"},{"key":"175_CR54","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1128\/JVI.00065-11","volume":"85","author":"DY Kim","year":"2011","unstructured":"Kim DY, Atasheva S, Foy NJ, Wang E, Frolova EI, Weaver S, Frolov I (2011) Design of chimeric alphaviruses with a programmed, attenuated, cell type-restricted phenotype. J Virol 85:4363\u20134376","journal-title":"J Virol"},{"key":"175_CR55","doi-asserted-by":"crossref","unstructured":"Kose N, Fox JM, Sapparapu G, Bombardi R, Tennekoon RN, de Silva AD, Elbashir SM, Theisen MA, Humphris-Narayanan E, Ciaramella G, Himansu S, Diamond MS, Crowe JE (2019) A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against Chikungunya infection. Sci Immunol 4:eaaw6647","DOI":"10.1126\/sciimmunol.aaw6647"},{"key":"175_CR56","doi-asserted-by":"crossref","first-page":"6142","DOI":"10.1016\/j.vaccine.2012.07.072","volume":"30","author":"M Kumar","year":"2012","unstructured":"Kumar M, Sudeep AB, Arankalle VA (2012) Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against Chikungunya virus. Vaccine 30:6142\u20136149","journal-title":"Vaccine"},{"key":"175_CR57","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.3201\/eid2008.140268","volume":"20","author":"RS Lanciotti","year":"2014","unstructured":"Lanciotti RS, Valadere AM (2014) Transcontinental movement of Asian genotype Chikungunya virus. Emerging Infect Dis 20:1400\u20131402","journal-title":"Emerging Infect Dis"},{"key":"175_CR58","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1111\/jgs.15104","volume":"65","author":"PO Lang","year":"2017","unstructured":"Lang PO, Loulergue P, Aspinall R (2017) Chikungunya Virus Infection: Why Should U.S. Geriatricians Be Aware of It? J Am Geriatr Soc 65:2529\u20132534","journal-title":"J Am Geriatr Soc"},{"key":"175_CR59","doi-asserted-by":"crossref","unstructured":"Langsjoen RM, Haller SL, Roy CJ, Vinet-Oliphant H, Bergren NA, Erasmus JH, Livengood JA, Powell TD, Weaver SC, Rossi SL (2018) Chikungunya virus strains show lineage-specific variations in virulence and cross-protective ability in murine and nonhuman primate models. mBio 9:e02449\u201317\u201313","DOI":"10.1128\/mBio.02449-17"},{"key":"175_CR60","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(14)60185-9","volume":"383","author":"I Leparc-Goffart","year":"2014","unstructured":"Leparc-Goffart I, Nougairede A, Cassadou S, Prat C, de Lamballerie X (2014) Chikungunya in the Americas. Lancet 383:514","journal-title":"Lancet"},{"key":"175_CR61","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0264-410X(86)90003-4","volume":"4","author":"NH Levitt","year":"1986","unstructured":"Levitt NH, Ramsburg HH, Hasty SE, Repik PM, Cole FE, Lupton HW (1986) Development of an attenuated strain of Chikungunya virus for use in vaccine production. Vaccine 4:157\u2013162","journal-title":"Vaccine"},{"key":"175_CR62","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1016\/j.vaccine.2012.10.016","volume":"31","author":"O Levy","year":"2013","unstructured":"Levy O, Goriely S, Kollmann TR (2013) Immune response to vaccine adjuvants during the first year of life. Vaccine 31:2500\u20132505","journal-title":"Vaccine"},{"key":"175_CR63","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.immuni.2010.10.004","volume":"33","author":"MA Liu","year":"2010","unstructured":"Liu MA (2010) Immunologic basis of vaccine vectors. Immunity 33:504\u2013515","journal-title":"Immunity"},{"key":"175_CR64","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/j.vaccine.2016.11.097","volume":"35","author":"J Lloyd","year":"2017","unstructured":"Lloyd J, Cheyne J (2017) The origins of the vaccine cold chain and a glimpse of the future. Vaccine 35:2115\u20132120","journal-title":"Vaccine"},{"key":"175_CR65","doi-asserted-by":"crossref","unstructured":"Lum F-M, Teo T-H, Lee WWL, Kam Y-W, REnia L, Ng LFP (2013) An essential role of antibodies in the control of Chikungunya virus infection. J Immunol 190:6295\u20136302","DOI":"10.4049\/jimmunol.1300304"},{"key":"175_CR66","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1089\/hum.2013.235","volume":"25","author":"D Majhen","year":"2014","unstructured":"Majhen D, Calderon H, Chandra N, Fajardo CA, Rajan A, Alemany R, Custers J (2014) Adenovirus-based vaccines for fighting infectious diseases and cancer: progress in the field. Human Gene Ther 25:301\u2013317","journal-title":"Human Gene Ther"},{"key":"175_CR67","doi-asserted-by":"crossref","first-page":"e928","DOI":"10.1371\/journal.pntd.0000928","volume":"5","author":"K Mallilankaraman","year":"2011","unstructured":"Mallilankaraman K, Shedlock DJ, Bao H, Kawalekar OU, Fagone P, Ramanathan AA, Ferraro B, Stabenow J, Vijayachari P, Sundaram SG, Muruganandam N, Sarangan G, Srikanth P, Khan AS, Lewis MG, Kim JJ, Sardesai NY, Muthumani K, Weiner DB (2011) A DNA vaccine against Chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl Trop Dis 5:e928","journal-title":"PLoS Negl Trop Dis"},{"key":"175_CR69","doi-asserted-by":"crossref","first-page":"e2343","DOI":"10.1371\/journal.pntd.0002343","volume":"7","author":"I Messaoudi","year":"2013","unstructured":"Messaoudi I, Vomaske J, Totonchy T, Kreklywich CN, Haberthur K, Springgay L, Brien JD, Diamond MS, Defilippis VR, Streblow DN (2013) Chikungunya virus infection results in higher and persistent viral replication in aged rhesus macaques due to defects in anti-viral immunity. PLoS Negl Trop Dis 7:e2343","journal-title":"PLoS Negl Trop Dis"},{"key":"175_CR70","doi-asserted-by":"crossref","first-page":"e2124","DOI":"10.1371\/journal.pntd.0002124","volume":"7","author":"SW Metz","year":"2013","unstructured":"Metz SW, Gardner J, Geertsema C, Le TT, Goh L, Vlak JM, Suhrbier A, Pijlman GP (2013a) Effective Chikungunya virus-like particle vaccine produced in insect cells. PLoS Negl Trop Dis 7:e2124","journal-title":"PLoS Negl Trop Dis"},{"key":"175_CR71","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.1016\/j.vaccine.2013.09.045","volume":"31","author":"SW Metz","year":"2013","unstructured":"Metz SW, Martina BE, van den Doel P, Geertsema C, Osterhaus AD, Vlak JM, Pijlman GP (2013b) Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits. Vaccine 31:6092\u20136096","journal-title":"Vaccine"},{"key":"175_CR72","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.smim.2017.08.014","volume":"34","author":"MO Mohsen","year":"2017","unstructured":"Mohsen MO, Zha L, Cabral-Miranda G, Bachmann MF (2017) Major findings and recent advances in virus-like particle (VLP)-based vaccines. Semin Immunol 34:123\u2013132","journal-title":"Semin Immunol"},{"key":"175_CR73","first-page":"32","volume":"178","author":"TE Morrison","year":"2011","unstructured":"Morrison TE, Oko L, Montgomery SA, Whitmore AC, Lotstein AR, Gunn BM, Elmore SA, Heise MT (2011) A mouse model of Chikungunya virus-induced musculoskeletal inflammatory disease. AJPA 178:32\u201340","journal-title":"AJPA"},{"key":"175_CR74","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/978-1-4899-1382-1_2","volume":"397","author":"B Moss","year":"1996","unstructured":"Moss B, Carroll MW, Wyatt LS, Bennink JR, Hirsch VM, Goldstein S, Elkins WR, Fuerst TR, Lifson JD, Piatak M, Restifo NP, Overwijk W, Chamberlain R, Rosenberg SA, Sutter G (1996) Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv Exp Med Biol 397:7\u201313","journal-title":"Adv Exp Med Biol"},{"key":"175_CR75","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s11262-017-1486-3","volume":"53","author":"MD M\u00fchlebach","year":"2017","unstructured":"M\u00fchlebach MD (2017) Vaccine platform recombinant measles virus. Virus Genes 53:733\u2013740","journal-title":"Virus Genes"},{"key":"175_CR76","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1016\/j.vaccine.2008.03.060","volume":"26","author":"K Muthumani","year":"2008","unstructured":"Muthumani K, Lankaraman KM, Laddy DJ, Sundaram SG, Chung CW, Sako E, Wu L, Khan A, Sardesai N, Kim JJ, Vijayachari P, Weiner DB (2008) Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus. Vaccine 26:5128\u20135134","journal-title":"Vaccine"},{"key":"175_CR77","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/infdis\/jiw111","volume":"214","author":"K Muthumani","year":"2016","unstructured":"Muthumani K, Block P, Flingai S, Muruganantham N, Chaaithanya IK, Tingey C, Wise M, Reuschel EL, Chung C, Muthumani A, Sarangan G, Srikanth P, Khan AS, Vijayachari P, Sardesai NY, Kim JJ, Ugen KE, Weiner DB (2016) Rapid and long-term immunity elicited by DNA-encoded antibody prophylaxis and DNA vaccination against Chikungunya virus. J Infect Dis 214:369\u2013378","journal-title":"J Infect Dis"},{"key":"175_CR78","first-page":"559","volume":"48","author":"E Nakao","year":"1973","unstructured":"Nakao E, Hotta S (1973) Immunogenicity of purified, inactivated Chikungunya virus in monkeys. Bull World Health Organ 48:559\u2013562","journal-title":"Bull World Health Organ"},{"key":"175_CR79","doi-asserted-by":"crossref","unstructured":"Nasar F, Gorchakov RV, Tesh RB, Weaver SC (2015) Eilat virus host range restriction is present at multiple levels of the virus life cycle. J Virol (5 ed.) 89:1404\u20131418","DOI":"10.1128\/JVI.01856-14"},{"key":"175_CR80","doi-asserted-by":"crossref","first-page":"e1003312","DOI":"10.1371\/journal.ppat.1003312","volume":"9","author":"P Pal","year":"2013","unstructured":"Pal P, Dowd KA, Brien JD, Edeling MA, Gorlatov S, Johnson S, Lee I, Akahata W, Nabel GJ, Richter MKS, Smit JM, Fremont DH, Pierson TC, Heise MT, Diamond MS (2013) Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus. PLoS Pathog 9:e1003312","journal-title":"PLoS Pathog"},{"key":"175_CR81","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1016\/j.vaccine.2012.04.099","volume":"30","author":"CD Partidos","year":"2012","unstructured":"Partidos CD, Paykel J, Weger J, Borland EM, Powers AM, Seymour R, Weaver SC, Stinchcomb DT, Osorio JE (2012) Cross-protective immunity against o\u2018nyong-nyong virus afforded by a novel recombinant Chikungunya vaccine. Vaccine 30:4638\u20134643","journal-title":"Vaccine"},{"key":"175_CR82","doi-asserted-by":"crossref","first-page":"6748","DOI":"10.1128\/JVI.03357-12","volume":"87","author":"A Piper","year":"2013","unstructured":"Piper A, Ribeiro M, Smith KM, Briggs CM, Huitt E, Nanda K, Spears CJ, Quiles M, Cullen J, Thomas ME, Brown DT, Hernandez R (2013) Chikungunya virus host range E2 transmembrane deletion mutants induce protective immunity against challenge in C57BL\/6\u00a0J Mice. J Virol 87:6748\u20136757","journal-title":"J Virol"},{"key":"175_CR83","doi-asserted-by":"crossref","first-page":"e1002142","DOI":"10.1371\/journal.ppat.1002142","volume":"7","author":"K Plante","year":"2011","unstructured":"Plante K, Wang E, Partidos CD, Weger J, Gorchakov R, Tsetsarkin K, Borland EM, Powers AM, Seymour R, Stinchcomb DT, Osorio JE, Frolov I, Weaver SC (2011) Novel Chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism. PLoS Pathog 7:e1002142","journal-title":"PLoS Pathog"},{"key":"175_CR84","doi-asserted-by":"crossref","first-page":"e0004007","DOI":"10.1371\/journal.pntd.0004007","volume":"9","author":"KS Plante","year":"2015","unstructured":"Plante KS, Rossi SL, Bergren NA, Seymour RL, Weaver SC (2015) Extended preclinical safety, efficacy and stability testing of a live-attenuated Chikungunya Vaccine candidate. PLoS Negl Trop Dis 9:e0004007\u201319","journal-title":"PLoS Negl Trop Dis"},{"key":"175_CR85","doi-asserted-by":"crossref","first-page":"e3354","DOI":"10.1371\/journal.pntd.0003354","volume":"8","author":"YS Poo","year":"2014","unstructured":"Poo YS, Rudd PA, Gardner J, Wilson JAC, Larcher T, Colle M-A, Le TT, Nakaya HI, Warrilow D, Allcock R, Bielefeldt-Ohmann H, Schroder WA, Khromykh AA, Lopez JA, Suhrbier A (2014) Multiple immune factors are involved in controlling acute and chronic Chikungunya virus infection. PLoS Negl Trop Dis 8:e3354\u201315","journal-title":"PLoS Negl Trop Dis"},{"key":"175_CR86","doi-asserted-by":"crossref","first-page":"S500","DOI":"10.1093\/infdis\/jiw369","volume":"214","author":"K Ramsauer","year":"2016","unstructured":"Ramsauer K, Tangy F (2016) Chikungunya virus vaccines: viral vector-based approaches. J Infect Dis 214:S500\u2013S505","journal-title":"J Infect Dis"},{"key":"175_CR87","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1473-3099(15)70043-5","volume":"15","author":"K Ramsauer","year":"2015","unstructured":"Ramsauer K, Schwameis M, Firbas C, M\u00fcllner M, Putnak RJ, Thomas SJ, Despr\u00e8s P, Tauber E, Jilma B, Tangy F (2015) Immunogenicity, safety, and tolerability of a recombinant measles-virus-based Chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. Lancet Infect Dis 15:519\u2013527","journal-title":"Lancet Infect Dis"},{"key":"175_CR88","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/nm.3409","volume":"19","author":"SG Reed","year":"2013","unstructured":"Reed SG, Orr MT, Fox CB (2013) Key roles of adjuvants in modern vaccines. Nat Med 19:1597\u20131608","journal-title":"Nat Med"},{"key":"175_CR89","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1016\/S0140-6736(18)32488-7","volume":"392","author":"EC Reisinger","year":"2019","unstructured":"Reisinger EC, Tschismarov R, Beubler E, Wiedermann U, Firbas C, Loebermann M, Pfeiffer A, Muellner M, Tauber E, Ramsauer K (2019) Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial. Lancet 392:2718\u20132727","journal-title":"Lancet"},{"key":"175_CR90","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1128\/JVI.73.5.3723-3732.1999","volume":"73","author":"A Roberts","year":"1999","unstructured":"Roberts A, Buonocore L, Price R, Forman J, Rose JK (1999) Attenuated vesicular stomatitis viruses as vaccine vectors. J Virol 73:3723\u20133732","journal-title":"J Virol"},{"key":"175_CR91","doi-asserted-by":"crossref","first-page":"e83527","DOI":"10.1172\/jci.insight.83527","volume":"2","author":"P Roques","year":"2017","unstructured":"Roques P, Ljungberg K, K\u00fcmmerer BM, Gosse L, Dereuddre-Bosquet N, Tchitchek N, Halleng\u00e4rd D, Garc\u00eda-Arriaza J, Meinke A, Esteban M, Merits A, Le Grand R, Liljestr\u00f6m P (2017) Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus. JCI Insight 2:e83527","journal-title":"JCI Insight"},{"key":"175_CR92","doi-asserted-by":"crossref","unstructured":"Rossi SL, Comer JE, Wang E, Azar SR, Lawrence WS, Plante JA, Ramsauer K, Schrauf S, Weaver SC (2019) Immunogenicity and efficacy of a measles virus-vectored Chikungunya vaccine in nonhuman primates. J Infect Dis","DOI":"10.1093\/infdis\/jiz202"},{"key":"175_CR93","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1093\/infdis\/jiu014","volume":"209","author":"CJ Roy","year":"2014","unstructured":"Roy CJ, Adams AP, Wang E, Plante K, Gorchakov R, Seymour RL, Vinet-Oliphant H, Weaver SC (2014) Chikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose. J Infect Dis 209:1891\u20131899","journal-title":"J Infect Dis"},{"key":"175_CR94","doi-asserted-by":"crossref","first-page":"9888","DOI":"10.1128\/JVI.00956-12","volume":"86","author":"PA Rudd","year":"2012","unstructured":"Rudd PA, Wilson J, Gardner J, Larcher T, Babarit C, Le TT, Anraku I, Kumagai Y, Loo YM, Gale M, Akira S, Khromykh AA, Suhrbier A (2012) Interferon response factors 3 and 7 protect against Chikungunya virus hemorrhagic fever and shock. J Virol 86:9888\u20139898","journal-title":"J Virol"},{"key":"175_CR95","doi-asserted-by":"crossref","unstructured":"Sahadeo NSD, Allicock OM, De Salazar PM, Auguste AJ, Widen S, Olowokure B, Gutierrez C, Valadere AM, Polson-Edwards K, Weaver SC, Carrington CVF (2017) Understanding the evolution and spread of Chikungunya virus in the Americas using complete genome sequences. Virus Evol 3:vex010\u201310","DOI":"10.1093\/ve\/vex010"},{"key":"175_CR96","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1099\/mic.0.049601-0","volume":"159","author":"M Saxena","year":"2013","unstructured":"Saxena M, Van TTH, Baird FJ, Coloe PJ, Smooker PM (2013) Pre-existing immunity against vaccine vectors\u2013friend or foe? Microbiology (Reading, England) 159:1\u201311","journal-title":"Microbiology (Reading, England)"},{"key":"175_CR97","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.trstmh.2009.07.014","volume":"104","author":"T Seyler","year":"2010","unstructured":"Seyler T, Hutin Y, Ramanchandran V, Ramakrishnan R, Manickam P, Murhekar M (2010) Estimating the burden of disease and the economic cost attributable to chikungunya, Andhra Pradesh, India, 2005\u20132006. Trans R Soc Trop Med Hyg 104:133\u2013138","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"175_CR98","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ijid.2018.11.058","volume":"79","author":"C Shaw","year":"2019","unstructured":"Shaw C, Panther L, August A, Zaks T, Smolenov I, Bart S, Watson M (2019) Safety and immunogenicity of a mRNA-based Chikungunya vaccine in a phase 1 dose-ranging trial. Int J Infect Dis 79:17","journal-title":"Int J Infect Dis"},{"key":"175_CR99","doi-asserted-by":"crossref","first-page":"471","DOI":"10.4149\/av_2013_04_471","volume":"57","author":"PJ Sheela","year":"2013","unstructured":"Sheela PJ, Sumathy K (2013) Serological correlates of immune protection conferred by Chikungunya virus infection. Acta Virol 57:471\u2013473","journal-title":"Acta Virol"},{"key":"175_CR100","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.3201\/eid2207.160116","volume":"22","author":"G Simmons","year":"2016","unstructured":"Simmons G, Br\u00e8s V, Lu K, Liss NM, Brambilla DJ, Ryff KR, Bruhn R, Velez E, Ocampo D, Linnen JM, Latoni G, Petersen LR, Williamson PC, Busch MP (2016) High incidence of Chikungunya virus and frequency of viremic blood donations during epidemic, Puerto Rico, USA, 2014. Emerg Infect Dis 22:1221\u20131228","journal-title":"Emerg Infect Dis"},{"key":"175_CR101","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.chom.2015.06.009","volume":"18","author":"SA Smith","year":"2015","unstructured":"Smith SA, Silva LA, Fox JM, Flyak AI, Kose N, Sapparapu G, Khomandiak S, Khomadiak S, Ashbrook AW, Kahle KM, Fong RH, Swayne S, Doranz BJ, McGee CE, Heise MT, Pal P, Brien JD, Austin SK, Diamond MS, Dermody TS, Crowe JE (2015) Isolation and characterization of broad and ultrapotent human monoclonal antibodies with therapeutic activity against Chikungunya virus. Cell Host Microbe 18:86\u201395","journal-title":"Cell Host Microbe"},{"key":"175_CR103","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1128\/mr.58.3.491-562.1994","volume":"58","author":"JH Strauss","year":"1994","unstructured":"Strauss JH, Strauss EG (1994) The alphaviruses: gene expression, replication, and evolution. Microbiol Rev 58:491\u2013562","journal-title":"Microbiol Rev"},{"key":"175_CR104","doi-asserted-by":"crossref","unstructured":"Sun S, Xiang Y, Akahata W, Holdaway H, Pal P, Zhang X, Diamond MS, Nabel GJ, Rossmann MG (2013) Structural analyses at pseudo atomic resolution of Chikungunya virus and antibodies show mechanisms of neutralization. eLife 2:e00435","DOI":"10.7554\/eLife.00435"},{"key":"175_CR105","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1089\/vim.2005.18.317","volume":"18","author":"F Tangy","year":"2005","unstructured":"Tangy F, Naim HY (2005) Live attenuated measles vaccine as a potential multivalent pediatric vaccination vector. Viral Immunol 18:317\u2013326","journal-title":"Viral Immunol"},{"key":"175_CR106","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1099\/vir.0.071282-0","volume":"96","author":"A Taylor","year":"2015","unstructured":"Taylor A, Herrero LJ, Rudd PA, Mahalingam S (2015) Mouse models of alphavirus-induced inflammatory disease. J Gen Virol 96:221\u2013238","journal-title":"J Gen Virol"},{"key":"175_CR107","doi-asserted-by":"crossref","first-page":"259","DOI":"10.4049\/jimmunol.1202177","volume":"190","author":"TH Teo","year":"2012","unstructured":"Teo TH, Lum FM, Claser C, Lulla V, Lulla A, Merits A, Renia L, Ng LFP (2012a) A pathogenic role for CD4+\u2009T cells during Chikungunya virus infection in mice. J Immunol 190:259\u2013269","journal-title":"J Immunol"},{"key":"175_CR108","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s12026-012-8266-x","volume":"53","author":"T-H Teo","year":"2012","unstructured":"Teo T-H, Lum F-M, Lee WWL, Ng LFP (2012b) Mouse models for Chikungunya virus: deciphering immune mechanisms responsible for disease and pathology. Immunol Res 53:136\u2013147","journal-title":"Immunol Res"},{"key":"175_CR109","doi-asserted-by":"crossref","unstructured":"Teo T-H, Her Z, Tan JJL, Lum F-M, Lee WWL, Chan Y-H, Ong R-Y, Kam Y-W, Leparc-Goffart I, Gallian P, REnia L, de Lamballerie X, Ng LFP (2015) Caribbean and La R\u00e9union Chikungunya virus isolates differ in their capacity to induce pro-inflammatory Th1 and NK cell responses and acute joint pathology. J Virol JVI.00909\u201315\u201359","DOI":"10.1128\/JVI.00909-15"},{"key":"175_CR110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2017.06.006","volume":"47","author":"EA Thompson","year":"2017","unstructured":"Thompson EA, Lor\u00e9 K (2017) Non-human primates as a model for understanding the mechanism of action of toll-like receptor-based vaccine adjuvants. Curr Opin Immunol 47:1\u20137","journal-title":"Curr Opin Immunol"},{"key":"175_CR111","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/j.vaccine.2009.02.062","volume":"27","author":"M Tiwari","year":"2009","unstructured":"Tiwari M, Parida M, Santhosh SR, Khan M, Dash PK, Rao PVL (2009) Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus. Vaccine 27:2513\u20132522","journal-title":"Vaccine"},{"key":"175_CR112","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1093\/infdis\/jiu114","volume":"209","author":"I Tretyakova","year":"2014","unstructured":"Tretyakova I, Hearn J, Wang E, Weaver S, Pushko P (2014) DNA vaccine initiates replication of live attenuated Chikungunya virus in vitro and elicits protective immune response in mice. J Infect Dis 209:1882\u20131890","journal-title":"J Infect Dis"},{"key":"175_CR113","doi-asserted-by":"crossref","first-page":"e1002412","DOI":"10.1371\/journal.ppat.1002412","volume":"7","author":"KA Tsetsarkin","year":"2011","unstructured":"Tsetsarkin KA, Weaver SC (2011) Sequential adaptive mutations enhance efficient vector switching by Chikungunya virus and its epidemic emergence. PLoS Pathog 7:e1002412","journal-title":"PLoS Pathog"},{"key":"175_CR114","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1089\/vbz.2006.6.325","volume":"6","author":"K Tsetsarkin","year":"2006","unstructured":"Tsetsarkin K, Higgs S, McGee CE, de Lamballerie X, Charrel RN, Vanlandingham DL (2006) Infectious clones of Chikungunya virus (La R\u00e9union isolate) for vector competence studies. Vector-Borne and Zoonotic Dis 6:325\u2013337","journal-title":"Vector-Borne and Zoonotic Dis"},{"key":"175_CR115","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1371\/journal.ppat.0030201","volume":"3","author":"KA Tsetsarkin","year":"2007","unstructured":"Tsetsarkin KA, Vanlandingham DL, McGee CE, Higgs S (2007) A single mutation in Chikungunya virus affects vector specificity and epidemic potential. PLoS Pathog 3:e201","journal-title":"PLoS Pathog"},{"key":"175_CR116","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.coviro.2016.02.007","volume":"16","author":"KA Tsetsarkin","year":"2016","unstructured":"Tsetsarkin KA, Chen R, Weaver SC (2016) Interspecies transmission and chikungunya virus emergence. Curr Opin Virol 16:143\u2013150","journal-title":"Curr Opin Virol"},{"key":"175_CR117","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/nbt1261","volume":"24","author":"JB Ulmer","year":"2006","unstructured":"Ulmer JB, Valley U, Rappuoli R (2006) Vaccine manufacturing: challenges and solutions. Nat Biotechnol 24:1377\u20131383","journal-title":"Nat Biotechnol"},{"key":"175_CR118","doi-asserted-by":"crossref","first-page":"e3101","DOI":"10.1371\/journal.pntd.0003101","volume":"8","author":"P van den Doel","year":"2014","unstructured":"van den Doel P, Volz A, Roose JM, Sewbalaksing VD, Pijlman GP, van Middelkoop I, Duiverman V, van de Wetering E, Sutter G, Osterhaus ADME, Martina BEE (2014) Recombinant modified vaccinia virus Ankara expressing glycoprotein E2 of Chikungunya virus protects AG129 mice against lethal challenge. PLoS Negl Trop Dis 8:e3101","journal-title":"PLoS Negl Trop Dis"},{"key":"175_CR119","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.3390\/v7072792","volume":"7","author":"MKS van Duijl-Richter","year":"2015","unstructured":"van Duijl-Richter MKS, Hoornweg TE, Rodenhuis-Zybert IA, Smit JM (2015) Early events in Chikungunya virus infection-from virus cell binding to membrane fusion. Viruses 7:3647\u20133674","journal-title":"Viruses"},{"key":"175_CR120","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.coviro.2013.04.003","volume":"3","author":"M-C Vaney","year":"2013","unstructured":"Vaney M-C, Duquerroy S, Rey FA (2013) Alphavirus structure: activation for entry at the target cell surface. Curr Opin Virol 3:151\u2013158","journal-title":"Curr Opin Virol"},{"key":"175_CR121","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.ibmb.2005.05.008","volume":"35","author":"DL Vanlandingham","year":"2005","unstructured":"Vanlandingham DL, Tsetsarkin K, Hong C, Klingler K, McElroy KL, Lehane MJ, Higgs S (2005) Development and characterization of a double subgenomic Chikungunya virus infectious clone to express heterologous genes in Aedes aegypti mosquitoes. Insect Biochem Mol Biol 35:1162\u20131170","journal-title":"Insect Biochem Mol Biol"},{"key":"175_CR122","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1586\/14760584.2013.811208","volume":"12","author":"JP Vasilakos","year":"2013","unstructured":"Vasilakos JP, Tomai MA (2013) The use of toll-like receptor 7\/8 agonists as vaccine adjuvants. Expert Rev Vaccines 12:809\u2013819","journal-title":"Expert Rev Vaccines"},{"key":"175_CR123","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.1128\/JVI.01603-09","volume":"84","author":"SM Volk","year":"2010","unstructured":"Volk SM, Chen R, Tsetsarkin KA, Adams AP, Garcia TI, Sall AA, Nasar F, Schuh AJ, Holmes EC, Higgs S, Maharaj PD, Brault AC, Weaver SC (2010) Genome-scale phylogenetic analyses of Chikungunya virus reveal independent emergences of recent epidemics and various evolutionary rates. J Virol 84:6497\u20136504","journal-title":"J Virol"},{"key":"175_CR124","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/bs.aivir.2016.07.001","volume":"97","author":"A Volz","year":"2017","unstructured":"Volz A, Sutter G (2017) Modified vaccinia virus Ankara: history, value in basic research, and current perspectives for vaccine development. Adv Virus Res 97:187\u2013243","journal-title":"Adv Virus Res"},{"key":"175_CR125","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nature09555","volume":"468","author":"JE Voss","year":"2010","unstructured":"Voss JE, Vaney M-C, Duquerroy S, Vonrhein C, Girard-Blanc C, Crublet E, Thompson A, Bricogne G, Rey FA (2010) Glycoprotein organization of Chikungunya virus particles revealed by X-ray crystallography. Nature 468:709\u2013712","journal-title":"Nature"},{"key":"175_CR126","doi-asserted-by":"crossref","first-page":"5030","DOI":"10.1016\/j.vaccine.2008.07.054","volume":"26","author":"E Wang","year":"2008","unstructured":"Wang E, Volkova E, Adams AP, Forrester N, Xiao S-Y, Frolov I, Weaver SC (2008) Chimeric alphavirus vaccine candidates for Chikungunya. Vaccine 26:5030\u20135039","journal-title":"Vaccine"},{"key":"175_CR127","doi-asserted-by":"crossref","first-page":"9249","DOI":"10.1128\/JVI.00844-11","volume":"85","author":"E Wang","year":"2011","unstructured":"Wang E, Kim DY, Weaver SC, Frolov I (2011a) Chimeric Chikungunya viruses are nonpathogenic in highly sensitive mouse models but efficiently induce a protective immune response. J Virol 85:9249\u20139252","journal-title":"J Virol"},{"key":"175_CR128","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1016\/j.vaccine.2011.01.108","volume":"29","author":"D Wang","year":"2011","unstructured":"Wang D, Suhrbier A, Penn-Nicholson A, Woraratanadharm J, Gardner J, Luo M, Le TT, Anraku I, Sakalian M, Einfeld D, Dong JY (2011b) A complex adenovirus vaccine against chikungunya virus provides complete protection against viraemia and arthritis. Vaccine 29:2803\u20132809","journal-title":"Vaccine"},{"key":"175_CR129","doi-asserted-by":"crossref","first-page":"e2970","DOI":"10.1371\/journal.pntd.0002970","volume":"8","author":"J Weger-Lucarelli","year":"2014","unstructured":"Weger-Lucarelli J, Chu H, Aliota MT, Partidos CD, Osorio JE (2014) A novel MVA vectored Chikungunya virus vaccine elicits protective immunity in mice. PLoS Negl Trop Dis 8:e2970","journal-title":"PLoS Negl Trop Dis"},{"key":"175_CR130","doi-asserted-by":"crossref","first-page":"e0004163","DOI":"10.1371\/journal.pntd.0004163","volume":"9","author":"J Weger-Lucarelli","year":"2015","unstructured":"Weger-Lucarelli J, Aliota MT, Kamlangdee A, Osorio JE (2015) Identifying the role of E2 domains on alphavirus neutralization and protective immune responses. PLoS Negl Trop Dis 9:e0004163\u201317","journal-title":"PLoS Negl Trop Dis"},{"key":"175_CR131","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1099\/jgv.0.000263","volume":"96","author":"C Wei Chiam","year":"2015","unstructured":"Wei Chiam C, Fun Chan Y, Chai Ong K, Thong Wong K, Sam I-C (2015) Neurovirulence comparison of chikungunya virus isolates of the Asian and East\/Central\/South African genotypes from Malaysia. J Gen Virol 96:3243\u20133254","journal-title":"J Gen Virol"},{"key":"175_CR132","first-page":"e000376","volume":"9","author":"I-K Yoon","year":"2015","unstructured":"Yoon I-K, Alera MT, Lago CB, Tac-An IA, Villa D, Fernandez S, Thaisomboonsuk B, Klungthong C, Levy JW, Velasco JM, Roque VG, Salje H, Macareo LR, Hermann LL, Nisalak A, Srikiatkhachorn A (2015) High rate of subclinical Chikungunya virus infection and association of neutralizing antibody with protection in a prospective cohort in the Philippines. PLoS Negl Trop Dis 9:e000376","journal-title":"PLoS Negl Trop Dis"},{"key":"175_CR133","doi-asserted-by":"crossref","first-page":"133","DOI":"10.4269\/ajtmh.2008.79.133","volume":"79","author":"SA Ziegler","year":"2008","unstructured":"Ziegler SA, Lu L, da Rosa APAT, Xiao S-Y, Tesh RB (2008) An animal model for studying the pathogenesis of Chikungunya virus infection. Am J Trop Med Hyg 79:133\u2013139","journal-title":"Am J Trop Med Hyg"}],"container-title":["Current Topics in Microbiology and Immunology"],"original-title":[],"link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/82_2019_175","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T13:35:27Z","timestamp":1695044127000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/82_2019_175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":132,"URL":"https:\/\/doi.org\/10.1007\/82_2019_175","relation":{},"ISSN":["0070-217X","2196-9965"],"issn-type":[{"value":"0070-217X","type":"print"},{"value":"2196-9965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"24 July 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}